secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001628280-23-036706
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine reports Q3 net loss of $50.7M, cash runway through end 2024; provides pipeline updates
--------------------------------------------------------------------------------

- R&D expenses $41.0M (up 64% YoY); G&A $10.5M (up 59%); net loss widened to $50.7M from $29.4M.
- Cash, equivalents, and investments $178.8M as of Sept 30, 2023, down from $307.4M at Dec 31, 2022.
- FDA granted Rare Pediatric Drug designation for PM359 (CGD); IND-enabling studies started, IND filing planned for 2024.
- Preclinical data showed up to 50% liver editing in NHPs for GSD1b and up to 70% correction in photoreceptors for retinitis pigmentosa.
- U.S. PTO issued third patent covering Prime Editing systems with PEgRNA, Prime Editor protein, and optionally a recombinase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828023036706/0001628280-23-036706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828023036706/prme-20231103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-036706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer